Eyegate Pharmaceuticals Inc (NASDAQ:EYEG) saw unusually-high trading volume on Tuesday . Approximately 146,607 shares were traded during trading, an increase of 37% from the previous session’s volume of 107,098 shares.The stock last traded at $2.14 and had previously closed at $2.09.

EYEG has been the subject of a number of recent analyst reports. Noble Financial initiated coverage on shares of Eyegate Pharmaceuticals in a research report on Thursday, April 7th. They set a “buy” rating and a $10.00 price target for the company. Rodman & Renshaw restated a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Thursday, May 12th. Maxim Group restated a “hold” rating on shares of Eyegate Pharmaceuticals in a research report on Tuesday, June 28th. Finally, Chardan Capital restated a “buy” rating on shares of Eyegate Pharmaceuticals in a research report on Thursday, April 14th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Eyegate Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $9.00.

The stock has a 50-day moving average of $2.60 and a 200 day moving average of $3.01. The company’s market capitalization is $17.19 million.

In other Eyegate Pharmaceuticals news, major shareholder Ventech Capital Ii sold 29,400 shares of the stock in a transaction that occurred on Wednesday, June 8th. The shares were sold at an average price of $3.25, for a total value of $95,550.00. Following the transaction, the insider now directly owns 1,641,540 shares in the company, valued at $5,335,005. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Morton Goldberg sold 10,939 shares of the stock in a transaction that occurred on Tuesday, June 7th. The stock was sold at an average price of $3.31, for a total transaction of $36,208.09. Following the completion of the transaction, the director now owns 43,216 shares in the company, valued at $143,044.96. The disclosure for this sale can be found here.

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.